Akanda

Akanda EBITDA per Share

The EBITDA per Share of Akanda (AKAN) as of Oct 26, 2026 is -11.31 USD. In the previous year, EBITDA per Share was -145.75 USD — a change of -92.24% (higher).

EBITDA per Share

-11.31USD

YoY

-92.24%

Last updated:

EBITDA per Share of Akanda is 2025 -11.31 USD. EBITDA per Share of Akanda was 2024 -145.75 USD. It decreases by -92.24% higher compared to the previous year.

The Akanda EBITDA per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA per Share
Date
EBITDA per Share
Jan 1, 2019
-49.79 USD
Jan 1, 2020
-92.04 USD
Jan 1, 2021
-0.09 USD
Jan 1, 2022
-27,630.15 USD
Jan 1, 2023
-256.34 USD
Jan 1, 2024
-145.75 USD
Jan 1, 2025
-11.31 USD
The Akanda EBITDA per Share history
YEAREBITDA per ShareYoY
-11.31USD-92.24%
-145.75USD-43.14%
-256.34USD-99.07%
-27,630.15USD+31.08 M%
-0.09USD-99.90%
-92.04USD+84.84%
-49.79USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Akanda Stock analysis

What does Akanda do? Akanda Corp generates revenue through its cultivation, distribution, and corporate segments. The cultivation segment focuses on producing medical cannabis and biomass, while the distribution segment sells products like those from Holigen, a Portugal-based cultivator, manufacturer, and distributor, and CanMart, a UK-based pharmaceutical importer and distributor supplying pharmacies and clinics. Holigen operates a 20,000 square foot indoor facility near Lisbon for high-THC cannabis cultivation. The company’s supply chain includes Cansativa Group, an European medical cannabis importer and distributor, and Cellen Life Sciences Leva Clinic, a UK-based digital pain clinic. Holigen’s products are distributed through Akanda’s network, targeting medical cannabis patients globally. CanMart serves UK pharmacies and clinics, leveraging its pharmaceutical licensing. Cansativa Group and Cellen Life Sciences Leva Clinic are integral to the seed-to-patient supply chain, connecting cultivation with end users. The company monetizes its portfolio by supplying ethically sourced medical cannabis products to patients worldwide through these established brands. Akanda’s revenue streams are derived from the sale of medical cannabis products via Holigen’s cultivation, CanMart’s distribution, and the supply chain involving Cansativa Group and Cellen Life Sciences Leva Clinic. The cultivation segment produces biomass for distribution, while the distribution segment handles sales to healthcare providers and clinics. The corporate segment supports these operations with strategic oversight. Akanda is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Akanda stock

EBITDA per Share of Akanda is -11.31 USD in 2025.

EBITDA per Share of Akanda changed from -145.75 USD to -11.31 USD, representing a -92.24% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBITDA per Share Akanda since 2006 – with annual values, charts, and detailed analysis.

EBITDA per share divides EBITDA by shares outstanding, showing the operating cash earnings allocated to each share before depreciation and financing effects.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Akanda

All Key Metrics — Akanda